NCT01671592View on ClinicalTrials.gov

Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Colorectal NeoplasmsColorectal CancerColorectal CarcinomaColorectal TumorsNeoplasms, Colorectal
Interventions
BIOLOGICAL

DC Vaccine

Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Pawel Kalinski

OTHER

NCT01671592 - Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) | Biotech Hunter | Biotech Hunter